| 产品名 | |||
| MK-2206 2HCl | Akt | 肺癌,结肠直肠癌,乳腺癌 | Phase 2 |
| Selumetinib (AZD6244) | MEK | 肺癌,甲状腺癌,黑素瘤 | Phase 3 |
| PD0325901 | MEK | 结肠直肠癌,神经母细胞瘤 | Phase 1/2 |
| BI 2536 | PLK | 肺癌,白血病,淋巴瘤 | Phase 2 |
| Dactolisib (NVP-BEZ235) | PI3K | 膀胱癌,乳腺癌,肾细胞癌,前列腺癌 | Phase 2 |
| Veliparib (ABT-888) | PARP | 乳腺癌,肺癌 | Phase 3 |
| Navitoclax (ABT-263) | Bcl-2 | 前列腺癌,白血病,淋巴瘤 | Phase 3 |
| Pictilisib (GDC-0941) | PI3K | 乳腺癌,肺癌 | Phase 2 |
| Buparlisib (NVP-BKM120) | PI3K | 乳腺癌 | Phase 2 |
| ABT-737 | Bcl-2 | 卵巢癌 | Phase 3 |
| Entinostat (MS-275) | HDAC | 乳腺癌 | Phase 3 |
| BGJ398 (NVP-BGJ398) | FGFR | 黑素瘤,成胶质细胞瘤,白血病,胆管癌 | Phase 2 |
| Alisertib (MLN8237) | Aurora Kinase | 肺癌 | Phase 2 |
| AZD4547 | FGFR | 实体瘤,肺癌 | Phase 3 |
| AZD8055 | mTOR | 实体瘤,胶质瘤 | Phase 1 |
| Saracatinib (AZD0530) | Src | 阿尔茨海默病,前列腺癌 | Phase 2/3 |
| AZD7762 | Chk | 实体瘤 | Phase 1 |
| Dinaciclib (SCH727965) | CDK | 白血病 | Phase 1/2 |
| AZD1775 (MK-1775) | Wee1 | 卵巢癌 | Phase 2 |
| RO4929097 | Gamma-secretase | 黑色素瘤,肉瘤,结肠直肠癌,胰腺癌,前列腺癌,成胶质细胞瘤,肾癌 | Phase 2 |
| Galunisertib (LY2157299) | TGF-beta/Smad | 骨髓增生异常综合征 | Phase 2/3 |
| Fedratinib (SAR302503, TG101348) | JAK | 骨髓纤维化 | Phase 2 |
| INK 128 (MLN0128) | mTOR | 乳腺癌,肾癌,子宫内膜癌 | Phase 2 |
